| (USD) | Mar 2023 | Q/Q |
|---|---|---|
| Revenue | 0 | - |
| Operating Income | -5.4MM | - |
| Operating Expenses | 5.4MM | - |
| Net Income | -5.3MM | - |
| R&D | 3.7MM | - |
| G&A | 1.7MM | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
By Brad Sorensen, CFA NASDAQ:SLRX READ THE FULL SLRX RESEARCH REPORT Salarius Pharmaceuticals (NASDAQ:SLRX) continues to pursue a “strategic alternative” and continues to cut costs in order to extend its resources. We continue to be disappointed in this announcement as we continue to believe in the science behind the treatments being developed by Salarius but we are pleased to see the company
Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Company Implemented Significant Expense-reduction Measures to Extend Cash Runway HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, to
Company implementing a series of cost-savings measures designed to extend Salarius’ expected cash runway into the first half of 2025 Extended runway supports the generation of additional data from the ongoing Phase 1/2 clinical trials in hematologic cancers and Ewing sarcoma HOUSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, today annou
Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues Protein degrader portfolio now includes 17 issued patents across six patent families HOUSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), announces that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,773,080, titled “Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same.
Additional Ewing Sarcoma Patient in Company’s Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients Treated with Seclidemstat, Topotecan and Cyclophosphamide Reaches 60%HOUSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that the hematologic cancer Phase 1/2 clinical trial being conducted at the University of Texas MD Anderson Cancer Center (MDACC or MD Anderson) is now listed as active and rec
By Brad Sorensen, CFA NASDAQ:SLRX READ THE FULL SLRX RESEARCH REPORT Earnings Update • Salarius (NASDAQ:SLRX) announced a 3Q loss of $0.65 per share, compared to a $6.41 per share loss in the same quarter in 2022. • Cash and cash equivalents were $7.6 million at the end of 3Q, compared to $12.1 million at the end of 2022. Update Salarius Pharmaceuticals recently announced that it was exploring
FDA briefing included new Ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse patients achieved disease control and have not progressed after at least 14.5, 19.7 and 22.8 months Future development activities were identified; Salarius intends to submit an amended Ewing sarcoma clinical trial protocol HOUSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that it participated in a Type B End-of-Phase 2 (EOP2) meeting with th
FDA removed partial clinical hold for Ewing sarcoma Phase 1/2 study with seclidemstat SP-3164 targeted protein degrader received Investigational New Drug clearance from FDA Company to explore strategic alternatives and implement measures to extend its resources HOUSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new
By Brad Sorensen, CFA NASDAQ:SLRX READ THE FULL SLRX RESEARCH REPORT Salarius Pharmaceuticals (NASDAQ:SLRX) recently announced that it was exploring “strategic alternatives” and cutting costs in order to extend its resources. We are disappointed in this announcement as we continue to believe in the science behind the treatments being developed by Salarius. However, we understand that funding has
HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced plans to explore strategic alternatives and implement measures to extend its resources. “The second quarter and recent weeks were highlighted by significant advancements in both of our development programs, but after a review o